Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease

Nephron

Volumn 133, Issue 2, 2016, Pages 89-97

  De Vries, Eline F ^a   Rabelink, Ton J ^a   Van Den Hout, Wilbert B ^b  

^a Laboratory for Experimental Vascular Medicine   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic kidney disease; Cost effectiveness; Early assessment; End stage renal disease; State transition model

Indexed keywords

BIOLOGICAL PRODUCT;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; END STAGE RENAL DISEASE; FINLAND; HEALTH CARE COST; HUMAN; HUNGARY; ITALY; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SPAIN; STEM CELL TRANSPLANTATION; UNITED KINGDOM; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; INCIDENCE; KIDNEY FAILURE, CHRONIC; THEORETICAL MODEL;

COST-BENEFIT ANALYSIS; EUROPE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 84973533356     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000446548     Document Type: Article

References (27)

1. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
2. Kidney Health for Life (KH4L): Chronic Kidney Disease Multinational Inventory. Brussels, 2014.
3. De Wit GA, Ramsteijn PG, De Charro FT: Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215-232.
4. Ubel PA, Hirth RA, Chernew ME, Fendrick AM: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-1641.
5. Levy AR, Perkins RM, Johnston KM, Sullivan SD, Sood VC, Agnese W, Schnitzler MA: An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease. Int J Nephrol Renovasc Dis 2014; 7: 271-280.
6. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, Foley RN, Middleton RJ: Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis 2010; 56: 1072-1081.
7. Orlando LA, Owen WF, Matchar DB: Relationship between nephrologist care and progression of chronic kidney disease. N C Med J 2007; 68: 9-16.
8. De Charro FT, Ramsteyn PG: RENINE, a relational registry. Registratie Nierfunctievervanging Nederland. Nephrol Dial Transplant 1995; 10: 436-441.
9. StataCorp: Stata Survival Analysis and Epidemiological Tables Reference Manual Release 13. College Station, Stata Press, 2013.
10. OECD: Treatment of Renal Failure (Dialysis and Kidney Transplants). OECD Publishing, 2011.
11. Adarkwah CC, Gandjour A, Akkerman M, Evers S: To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective. Kidney Blood Press Res 2013; 37: 168-180.
12. Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, Gray A, Cass A, Baigent C, Landray MJ, Herrington W, Mihaylova B; SHARP Collaborative Group: What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol 2015; 16: 65.
13. Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S: Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. J Hypertens 2014; 32: 681-692.
14. Villa G, Fernández-Ortiz L, Cuervo J, Rebollo P, Selgas R, González T, Arrieta J: Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit Dial Int 2012; 32: 192-199.
15. Malmström RK, Roine RP, Heikkilä A, Räsänen P, Sintonen H, Muroma-Karttunen R, Honkanen E: Cost analysis and health-related quality of life of home and self-care satellite haemodialysis. Nephrol Dial Transplant 2008; 23: 1990-1996.
16. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242.
17. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM: Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68: 2801-2808.
18. Bass EB, Wills S, Fink NE, Jenckes MW, Sadler JH, Levey AS, Meyer K, Powe NR: How strong are patients' preferences in choices between dialysis modalities and doses? Am J Kidney Dis 2004; 44: 695-705.
19. EuroStat: Labour Force Survey. Brussels, European Commission, 2014. http://epp.eurostat. ec.europa.eu/cache/ITY-OFFPUB/KSSF-12-040/EN/KS-SF-12-040-EN.PDF (accessed October 2, 2014).
20. EuroStat: Labour Costs. Brussels, European Commission, 2014. http://epp.eurostat.ec.europa.eu/prtal/page/portal/labour-market/lobour-costs/database (accessed October 2, 2014).
21. Jansen DL, Rijken M, Heijmans MJWM, Kaptein AA, Groenewegen PP: Psychological and social aspects of living with chronic kidney disease; in Sahay M (ed): Chronic Kidney Disease and Renal Transplantation. InTech, 2012, pp 47-74.
22. Devlin N, Parkin D: Does NICE have a costeffectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
23. Boersma C, Broere A, Postma MJ: Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010; 13: 853-856.
24. Treharne C, Liu FX, Arici M, Crowe L, Farooqui U: Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective. Appl Health Econ Health Policy 2014; 12: 409-420.
25. Sennfält K, Magnusson M, Carlsson P: Comparison of hemodialysis and peritoneal dialysis - a cost-utility analysis. Perit Dial Int 2002; 22: 39-47.
26. Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C: Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010; 14: 1-184.
27. Couchoud C, Couillerot AL, Dantony E, Elsensohn MH, Labeeuw M, Villar E, Ecochard R, Bongiovanni I: Economic impact of a modification of the treatment trajectories of patients with end-stage renal disease. Nephrol Dial Transplant 2015; 30: 2054-2068.